Merck & Co, INC Form 4 insider transactions

Richard R. DeLuca, EVP & President of Merck Animal Health, reports acquisition of restricted stock units and stock options, along with adjustments in common stock holdings through dividend reinvestments and 401(k) plan activity.

Director Peter C. Wendell reports acquisition of phantom stock units and disposition of common stock in Merck & Co., Inc.

Christine E. Seidman, a director at Merck & Co., Inc., acquired phantom stock units on March 28, 2024, according to a Form 4 filing with the SEC.

Director Thomas H. Glocer reports acquisition of phantom stock units and holdings in Merck & Co., Inc.

Director Mary Ellen Coe reports acquisition of phantom stock units convertible to common stock in a recent transaction.

Merck & Co., Inc. finalizes the acquisition of Harpoon Therapeutics through a merger, resulting in Merck becoming the direct beneficial owner of 100% of Harpoon's common stock.